Vaughan David Investments LLC IL Has $77.91 Million Stake in AbbVie Inc. $ABBV

Vaughan David Investments LLC IL trimmed its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 2.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 336,464 shares of the company’s stock after selling 8,803 shares during the quarter. AbbVie accounts for about 1.7% of Vaughan David Investments LLC IL’s portfolio, making the stock its 7th largest position. Vaughan David Investments LLC IL’s holdings in AbbVie were worth $77,905,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ABBV. Evolution Wealth Management Inc. bought a new stake in shares of AbbVie in the second quarter worth $26,000. Spurstone Advisory Services LLC acquired a new position in AbbVie during the 2nd quarter worth about $28,000. Financial Gravity Companies Inc. bought a new stake in shares of AbbVie in the 2nd quarter valued at about $36,000. Bear Mountain Capital Inc. grew its position in shares of AbbVie by 480.6% in the 2nd quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock valued at $40,000 after buying an additional 173 shares during the last quarter. Finally, Delos Wealth Advisors LLC acquired a new stake in shares of AbbVie in the second quarter valued at about $39,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ABBV. Wall Street Zen lowered AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 3rd. Scotiabank started coverage on shares of AbbVie in a report on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 price target for the company. Evercore ISI boosted their price target on shares of AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a research report on Monday, September 22nd. UBS Group reiterated a “neutral” rating on shares of AbbVie in a research report on Tuesday, January 13th. Finally, HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and lifted their target price for the stock from $225.00 to $265.00 in a research note on Wednesday, December 10th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat, AbbVie currently has a consensus rating of “Moderate Buy” and an average target price of $248.11.

AbbVie Stock Down 1.1%

Shares of ABBV stock opened at $214.38 on Tuesday. The firm has a 50 day moving average of $226.72 and a 200-day moving average of $216.82. The company has a market cap of $378.89 billion, a price-to-earnings ratio of 162.41, a price-to-earnings-growth ratio of 0.88 and a beta of 0.36. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. The company had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. AbbVie’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be given a dividend of $1.73 per share. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.2%. AbbVie’s payout ratio is currently 524.24%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.